Boston Scientific touts 3-year outcomes for Synergy bioabsorbable drug-eluting stent
Data presented at ACC 2017 showed that Boston Scientific‘s (NYSE:BSX) Synergy bioabsorbable polymer drug-eluting stent was as efficacious as the company’s Promus Element Plus drug-eluting stent system, with a lower relative rate of stent thrombosis.
The 3-year Evolve II trial enrolled 1,684 patients with native coronary artery lesions and randomized patients to receive either the Synergy or Promus stent. The primary endpoint was target lesion failure at 12 months.
Get the full story at our sister site, Drug Delivery Business News.